[go: up one dir, main page]

WO2024197190A3 - Treatment of neuroinflammation - Google Patents

Treatment of neuroinflammation Download PDF

Info

Publication number
WO2024197190A3
WO2024197190A3 PCT/US2024/020999 US2024020999W WO2024197190A3 WO 2024197190 A3 WO2024197190 A3 WO 2024197190A3 US 2024020999 W US2024020999 W US 2024020999W WO 2024197190 A3 WO2024197190 A3 WO 2024197190A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
encephalitis
pain
chronic
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/020999
Other languages
French (fr)
Other versions
WO2024197190A2 (en
Inventor
Michael Kuran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kubota Vision Inc
Original Assignee
Kubota Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kubota Vision Inc filed Critical Kubota Vision Inc
Publication of WO2024197190A2 publication Critical patent/WO2024197190A2/en
Publication of WO2024197190A3 publication Critical patent/WO2024197190A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are compositions and methods for the treatment of neuroinflammatory diseases and conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (AES), multiple sclerosis (MS), traumatic brain injury (TBI), complex regional pain syndrome (CRPS), optic neuritis (ON), neuromyelitis optica (NMO), chronic traumatic encephalopathy (CTE), ischemic stroke (IS), Vascular dementia (VAD), Anti- myelin oligodendrocyte glycoprotein antibody disease (MOGAD), Transverse myelitis (TM), Autoimmune Encephalitis (AE), Acute disseminated encephalomyelitis (ADEM), Chronic meningitis (CM), Central nervous system (CNS) vasculitis, Hashimoto's encephalitis (HE), Neurosarcoidosis (NS), Multiple system atrophy (MSA), Migraine, Chemotherapy-induced pain or Dementia-related pain.
PCT/US2024/020999 2023-03-22 2024-03-21 Treatment of neuroinflammation Pending WO2024197190A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363454011P 2023-03-22 2023-03-22
US63/454,011 2023-03-22

Publications (2)

Publication Number Publication Date
WO2024197190A2 WO2024197190A2 (en) 2024-09-26
WO2024197190A3 true WO2024197190A3 (en) 2025-02-06

Family

ID=92842493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/020999 Pending WO2024197190A2 (en) 2023-03-22 2024-03-21 Treatment of neuroinflammation

Country Status (1)

Country Link
WO (1) WO2024197190A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210387975A1 (en) * 2018-09-28 2021-12-16 Acucela Inc. Inhibitors of vap-1
WO2021258159A1 (en) * 2020-06-26 2021-12-30 Pharmaxis Ltd. Haloallylamine dual amine oxidase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210387975A1 (en) * 2018-09-28 2021-12-16 Acucela Inc. Inhibitors of vap-1
WO2021258159A1 (en) * 2020-06-26 2021-12-30 Pharmaxis Ltd. Haloallylamine dual amine oxidase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HENEKA MICHAEL T, CARSON MONICA J, KHOURY JOSEPH EL, LANDRETH GARY E, BROSSERON FREDERIC, FEINSTEIN DOUGLAS L, JACOBS ANDREAS H, W: "Neuroinflammation in Alzheimer's disease", THE LANCET NEUROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 4, 1 April 2015 (2015-04-01), AMSTERDAM, NL, pages 388 - 405, XP093276887, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(15)70016-5 *

Also Published As

Publication number Publication date
WO2024197190A2 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
Miida et al. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects
NO20063381L (en) CB1 modulator connections
HUP9802862A2 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate and pharmaceutical compositions containing it for treating cns disorders
MA51520A (en) 1,3,4,5-TETRAHYDRO-2H-PYRIDO [4,3-B] DERIVATIVES INDOLE FOR THE TREATMENT, RELIEF OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES SUCH AS ALZHEIMER'S DISEASE
WO2024197190A3 (en) Treatment of neuroinflammation
MA26999A1 (en) USE OF INVERTED GABAA AGONISTS IN ASSOCIATION WITH PARTIAL AGONISTS OF NICOTINE RECEPTORS, ESTROGEN, SELECTIVE ESTROGEN MODULATORS OR VITAMIN E FOR THE TREATMENT OF COGNITIVE DISORDERS
EA201990450A1 (en) KINASE INHIBITORS CONTAINING A DOMAIN WITH TWO LEUCINE "Zipper" (DLK) FOR THE TREATMENT OF A DISEASE
EP4301747A4 (en) INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED THERETO
Valdo et al. Enhanced expression of NGF receptors in multiple sclerosis lesions
Behl et al. Exploring the potential role of rab5 protein in endo-lysosomal impairment in Alzheimer’s disease
Canitano et al. Autistic epileptiform regression
von Oertzen et al. Levetiracetam and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and epilepsy: a reasonable combination
Trabacca et al. Levetiracetam in nonconvulsive status epilepticus in childhood: a case report
Miano et al. The role of sleep-related cognitive functions in the spectrum of benign epilepsy with centro-temporal spikes
MA54530B1 (en) Dosage regimen for the use of ly3154207 in the treatment of dopaminergic central nervous system disorders
PT1656458E (en) Human autism susceptibility gene and uses thereof
Shushtarian et al. Blurred Vision in a Patient Suffering from Endometriosis and Epilepsy
Teggi et al. Otoneurological findings in human immunodeficiency virus positive patients
MX2024014769A (en) Apelin receptor modulators for treatment of a disorder or disease associated with bbb permeability
Gupta et al. Metronidazole induced neuropathy
FR3086517B1 (en) HAIR TREATMENT METHOD
Hagerman Etiology, diagnosis, and development in fragile X syndrome.
WO2022011314A8 (en) POLYMORPHS OF A GABAA α5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT
Masjuan et al. Behavioral impairment and amnesia at the onset of Susac syndrome
WO2021195331A3 (en) Compositions and methods for treating a neurodegenerative or developmental disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24775736

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: KR1020257034512

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2024775736

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024775736

Country of ref document: EP

Effective date: 20251022

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24775736

Country of ref document: EP

Kind code of ref document: A2